Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$417.86 USD

417.86
1,931,027

+3.85 (0.93%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks News

Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised

Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.

Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised

Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.

Ensign Group (ENSG) Beats on Q2 Earnings, Raises '23 EPS View

Ensign Group's (ENSG) second-quarter results benefit from improved occupancies, skilled and managed care revenue. Rising expenses acted as a partial offset.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up

Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

Centene (CNC) Q2 Earnings Beat Estimates on Membership Growth

Centene's (CNC) Q2 results benefit from growing premium and service revenues coupled with improving membership.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut

In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.

DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong

DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up

Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.

LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline

A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.

HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2023 EPS View

HCA Healthcare's (HCA) Q2 results benefit from improving patient volumes and surgeries. However, rising expenses acted as a partial offset.

Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up

The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.

Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.

CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View

CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

West Pharmaceutical (WST) Q2 Earnings Beat, HVP Drives Sales

West Pharmaceutical's (WST) second-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down

Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.

Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up

Align Technology (ALGN) delivers impressive earnings in the second quarter of 2023.

Teladoc Health (TDOC) Q2 Earnings Top Estimates on Lower Expenses

Teladoc Health's (TDOC) Q2 results reflect improving access fees and other revenues coupled with lower expenses.

Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.

Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View

Universal Health's (UHS) Q2 results indicate improved patient admissions and solid segmental performance. Management currently expects adjusted EPS within $9.85-$10.50 for 2023.

Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down

Challenging macroeconomic conditions and slowdown in activities in China impede Thermo Fisher's (TMO) Q2 revenues.

Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.

NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y

NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.

ELV or DOCS: Which Is the Better Value Stock Right Now?

ELV vs. DOCS: Which Stock Is the Better Value Option?